I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases-Reference-Cited by-同舟云学术

I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases

Published:2015-01-26 Issue:4 Volume:50 Page:607-609
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Yamamoto H,Uchida N,Matsuno N,Kon A,Nishida A,Ota H,Ikebe T,Nakano N,Ishiwata K,Araoka H,Takagi S,Tsuji M,Asano-Mori Y,Yamamoto G,Izutsu K,Masuoka K,Wake A,Yoneyama A,Makino S,Taniguchi S

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2014316.pdf

Reference13 articles.

1. Ciurea SO, Andersson BS . Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 523–536.

2. Horwitz ME, Morris A, Gasparetto C, Sullivan K, Long G, Chute J et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008; 14: 591–594.

3. Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10: 3586–3592.

4. Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008; 14: 583–590.

5. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE . Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102: 1915–1919.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examination of a nutritional treatment pathway according to pretreatment health status and stress levels of patients undergoing hematopoietic stem cell transplantation;PLOS ONE;2022-08-01

2. Complications after Cord Blood Transplantation: current and future perspectives;Japanese Journal of Transplantation and Cellular Therapy;2022

3. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies;Bone Marrow Transplantation;2021-03-03

4. Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies;International Journal of Hematology;2020-07-12

5. Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/ RBM15‐MKL1 in an adult patient following a non‐mediastinal germ cell tumour;British Journal of Haematology;2020-06-23